All Stories

  1. Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease

    Article • Brain Communications, January 2026, Oxford University Press (OUP)

    Dr Konstantinos Chiotis

  2. Regional [ 18 F]RO948 tau-PET across the AD continuum in relation to plasma biomarkers, cognition and atrophy

    Article • December 2025, openRxiv

    Dr Konstantinos Chiotis

  3. Tablet‐based Cognitive Assessment Tool (TabCAT) in a multisite study of early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, December 2025, Wiley

    Dr Konstantinos Chiotis, Dr. Raymond Scott Turner

  4. Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer’s disease compared to comorbid cases; proof of concept in the ADNI study

    Article • Molecular Psychiatry, August 2024, Springer Science + Business Media

    Dr Konstantinos Chiotis

  5. Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

    Article • Molecular Neurodegeneration, September 2023, Springer Science + Business Media

    Dr Konstantinos Chiotis

  6. Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic

    Article • Translational Psychiatry, July 2023, Springer Science + Business Media

    Dr Konstantinos Chiotis

  7. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline

    Article • Molecular Psychiatry, October 2021, Springer Science + Business Media

    Dr Konstantinos Chiotis

  8. [18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease

    Article • Molecular Psychiatry, July 2020, Springer Science + Business Media

    Dr Konstantinos Chiotis

  9. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging

    Article • European Journal of Pediatrics, March 2019, Springer Science + Business Media

    Dr Konstantinos Chiotis

  10. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis

    Article • European Journal of Pediatrics, March 2019, Springer Science + Business Media

    Dr Konstantinos Chiotis

  11. Tau PET imaging in neurodegenerative tauopathies—still a challenge

    Article • Molecular Psychiatry, January 2019, Springer Science + Business Media

    Dr Konstantinos Chiotis

  12. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease

    Article • European Journal of Pediatrics, January 2019, Springer Science + Business Media

    Dr Konstantinos Chiotis

  13. Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [18F]THK5317 PET

    Article • NeuroImage Clinical, January 2019, Elsevier

    Dr Konstantinos Chiotis

  14. Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease

    Article • European Journal of Pediatrics, December 2018, Springer Science + Business Media

    Dr Konstantinos Chiotis

  15. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species

    Article • NeuroImage Clinical, August 2018, Elsevier

    Dr Konstantinos Chiotis

  16. Spatial Normalization of18F-Flutemetamol PET Images Using an Adaptive Principal-Component Template

    Article • Journal of Nuclear Medicine, June 2018, Society of Nuclear Medicine

    Dr Konstantinos Chiotis

  17. Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain

    Article • European Journal of Pediatrics, May 2018, Springer Science + Business Media

    Dr Konstantinos Chiotis

  18. Tau positron emission tomography imaging in tauopathies: The added hurdle of off‐target binding

    Article • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, January 2018, Wiley

    Dr Konstantinos Chiotis

  19. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease

    Article • Alzheimer s & Dementia, December 2017, Wiley

    Dr Konstantinos Chiotis

  20. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

    Article • The Lancet Neurology, August 2017, Elsevier

    Dr Konstantinos Chiotis

  21. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer’s Disease in a Clinical Setting

    Article • Journal of Alzheimer’s Disease, July 2017, SAGE Publications

    Dr Konstantinos Chiotis

  22. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia

    Article • Molecular Psychiatry, May 2017, Nature

    Dr Konstantinos Chiotis

  23. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

    Article • Neurobiology of Aging, April 2017, Elsevier

    Dr Konstantinos Chiotis

  24. Tau PET imaging: present and future directions

    Article • Molecular Neurodegeneration, February 2017, Springer Science + Business Media

    Dr Konstantinos Chiotis

  25. Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease

    Article • Alzheimer s Research & Therapy, September 2016, Springer Science + Business Media

    Dr Konstantinos Chiotis

  26. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease

    Article • Journal of Cerebral Blood Flow & Metabolism, July 2016, SAGE Publications

    Dr Konstantinos Chiotis

  27. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

    Article • Brain, July 2016, Oxford University Press (OUP)

    Dr Konstantinos Chiotis

  28. Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm

    Article • European Journal of Pediatrics, March 2016, Springer Science + Business Media

    Dr Konstantinos Chiotis

  29. Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease

    Article • Journal of Nuclear Medicine, February 2016, Society of Nuclear Medicine

    Dr Konstantinos Chiotis

  30. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease

    Article • Brain, January 2016, Oxford University Press (OUP)

    Dr Konstantinos Chiotis

  31. Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology

    Article • Journal of Nuclear Medicine, January 2016, Society of Nuclear Medicine

    Dr Konstantinos Chiotis

  32. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging

    Article • European Journal of Pediatrics, July 2015, Springer Science + Business Media

    Dr Konstantinos Chiotis

  33. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease

    Article • Journal of Alzheimer’s Disease, April 2015, IOS Press

    Dr Konstantinos Chiotis

  34. Role of Anthropometric Characteristics in Idiopathic Carpal Tunnel Syndrome

    Article • Archives of Physical Medicine and Rehabilitation, April 2013, Elsevier

    Dr Konstantinos Chiotis